Scarica l'app Stockscreener
1.29
0.78%
0.01
Pre-mercato:
1.25
-0.04
-3.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CTSO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.28
Aprire:
$1.27
Volume 24 ore:
56,429
Relative Volume:
0.58
Capitalizzazione di mercato:
$66.37M
Reddito:
$33.79M
Utile/perdita netta:
$-18.67M
Rapporto P/E:
-3.6013
EPS:
-0.3582
Flusso di cassa netto:
$-19.17M
1 W Prestazione:
+7.50%
1M Prestazione:
+53.57%
6M Prestazione:
+41.76%
1 anno Prestazione:
+84.29%
Intervallo 1D:
$1.2523
$1.30
Intervallo di 1 settimana:
$1.10
$1.30
Portata 52W:
$0.7101
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Nome
Cytosorbents Corp
Settore
Industria
Telefono
973-329-8885
Indirizzo
305 COLLEGE ROAD EAST, PRINCETON, NJ
Confronta CTSO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
1.29 | 66.37M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
136.26 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.78 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.74 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.75 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.18 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-07 | Iniziato | B. Riley Securities | Buy |
| 2021-10-14 | Ripresa | B. Riley Securities | Buy |
| 2020-09-17 | Iniziato | Jefferies | Buy |
| 2020-09-01 | Iniziato | SVB Leerink | Outperform |
| 2017-08-08 | Reiterato | Maxim Group | Buy |
| 2016-10-26 | Iniziato | Aegis Capital | Buy |
| 2016-05-24 | Iniziato | Maxim Group | Buy |
| 2015-10-29 | Aggiornamento | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | Reiterato | MLV & Co | Buy |
| 2015-04-01 | Reiterato | MLV & Co | Buy |
| 2015-03-05 | Iniziato | MLV & Co | Buy |
| 2015-02-25 | Iniziato | WBB Securities | Speculative Buy |
| 2015-01-27 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Cytosorbents Corp Borsa (CTSO) Ultime notizie
Millennium Management LLC Buys Shares of 33,280 Cytosorbents Co. (NASDAQ:CTSO) - Defense World
Cytosorbents announces voting results from annual meeting By Investing.com - Investing.com Canada
Cytosorbents announces voting results from annual meeting - Investing.com
CytoSorbents Warrants Expire Worthless as Stock Price Fails Threshold - Investing.com
Cytosorbents Co. (NASDAQ:CTSO) Shares Purchased by Northern Trust Corp - Defense World
Critical Care Leader CytoSorbents Reveals Growth Strategy at Jefferies Healthcare Conference - Stock Titan
Cytosorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented At EuroPCR 2025 - marketscreener.com
CytoSorbents device cuts bleeding in CABG patients - Investing.com
New Clinical Data: How CytoSorbents' Breakthrough Device Slashes Severe Bleeding Risk in Urgent Heart Surgery - Stock Titan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - Defense World
Cytosorbents FY2025 EPS Forecast Lifted by HC Wainwright - Defense World
D. Boral Capital Reiterates “Buy” Rating for Cytosorbents (NASDAQ:CTSO) - Defense World
Cytosorbents (NASDAQ:CTSO) Earns Neutral Rating from HC Wainwright - Defense World
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2025 Earnings Call Transcript - Insider Monkey
Cytosorbents Corp’s Earnings Call: A Balanced Outlook - TipRanks
CytoSorbents (CTSO) Receives Neutral Rating from HC Wainwright & Co. | CTSO Stock News - GuruFocus
CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | - GuruFocus
CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | CTSO Stock News - GuruFocus
CytoSorbents: Q1 Earnings Snapshot - CT Insider
CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance
CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and Strengthening Financials - GuruFocus
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
CytoSorbents (CTSO) Targets Growth Amid Regulatory Challenges - GuruFocus
Earnings call transcript: CytoSorbents Q1 2025 misses earnings, stock dips - Investing.com
CytoSorbents Corp Q1 2025 Earnings: EPS of -$0.06 Beats Estimate, Revenue of $8.7M Misses Estimate - GuruFocus
CTSO Reports Q1 Revenue Below Expectations Amid Strategic Changes in Germany | CTSO Stock News - GuruFocus
CytoSorbents Corporation Q1 2025 Financial Results - TradingView
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Transcript : Cytosorbents Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Raymond James Financial Inc. Makes New Investment in Cytosorbents Co. (NASDAQ:CTSO) - Defense World
CytoSorbents Corp (CTSO) Q1 2025 Earnings Report Preview: What t - GuruFocus
CytoSorbents's Earnings: A Preview - Nasdaq
CytoSorbents Corp (CTSO) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Cytosorbents (CTSO) Projected to Post Earnings on Wednesday - Defense World
Cytosorbents’ (CTSO) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com - Defense World
CytoSorbents (CTSO) Stock: Analyst Maintains "Buy" Rating with $ - GuruFocus
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Today’s watch list includes Cytosorbents Corp (NASDAQ:CTSO) stock - uspostnews.com
CytoSorbents (CTSO) Stock: Analyst Maintains - GuruFocus
Demystifying CytoSorbents: Insights From 4 Analyst Reviews - Benzinga
FDA denies CytoSorbents’ request for DrugSorb-ATR device - Investing.com
CytoSorbents: FDA issues denial letter for De Novo Request for DrugSorb-ATR - TipRanks
CytoSorbents (CTSO) Awaits FDA Approval for Breakthrough Device DrugSorb-ATR | CTSO Stock News - GuruFocus
CytoSorbents Provides Regulatory Update for DrugSorb-ATR - PR Newswire
Cytosorbents (NASDAQ:CTSO) versus Microbot Medical (NASDAQ:MBOT) Financial Analysis - Defense World
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights - Longview News-Journal
CytoSorbents, Blood Purification Leader, Reveals Q1 2025 Results and Business Updates May 14 - Stock Titan
CytoSorbents secures $1.7M via NJ tax credit transfer - Investing.com
CytoSorbents Lands $1.7M Strategic Funding: New DrugSorb Product Launch and Manufacturing Expansion Ahead - Stock Titan
U.S. FDA Grants Breakthrough Designation To Cytosorb For Removal Of Ticagrelor During Cardiopulmonary Bypass In Emergent And Urgent Cardiothoracic Surgery - Reuters
Cytosorbents Corp Azioni (CTSO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytosorbents Corp Azioni (CTSO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MARIANI PETER J | Chief Financial Officer |
Dec 12 '24 |
Buy |
0.89 |
20,000 |
17,872 |
381,363 |
| MARIANI PETER J | Chief Financial Officer |
Dec 11 '24 |
Buy |
0.89 |
11,363 |
10,103 |
361,363 |
4.52%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):